BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nanosphere, Inc. IPO Raises $98 Million, Bottom of Range


11/1/2007 7:04:47 AM

NORTHBROOK, Ill., Nov. 1, 2007 (PRIME NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a nanotechnology-based molecular diagnostics company, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at $14.00 per share. All of the shares are being offered by Nanosphere. Nanosphere has granted to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Nanosphere's common stock began trading today on NASDAQ Global Market under the symbol ``NSPH.''

Credit Suisse Securities (USA) LLC acted as the sole book-running manager for the offering. Piper Jaffray & Co., Leerink Swann LLC, and Allen & Company LLC acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 31, 2007. This offering is being made solely by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Credit Suisse, Prospectus Department, One Madison Avenue, Level 1B, New York, NY 10010 (telephone number: (212) 325-2580).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Nanosphere, Inc.

Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene(r) System for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

The Nanosphere, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4344

Contact: Schwartz Communications, Inc. Laura Kempke Andrea tenBroek 781-684-0770 nanosphere@schwartz-pr.com

Source: Nanosphere, Inc.



Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES